Matching articles for "Osteoarthritis"
Issue 1645 · March 7, 2022
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive…

Med Lett Drugs Ther. 2022 Mar 7; 64(1645):33-40
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Issue 1596 · April 20, 2020
Drugs for Osteoarthritis

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical…

Med Lett Drugs Ther. 2020 Apr 20; 62(1596):57-62
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Issue 1585 · November 18, 2019
Turmeric Supplements

Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion,…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):185
Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion, cardiovascular health, depression, anxiety, memory, and cognition.
Issue 1581 · September 23, 2019
Qmiiz ODT - An Orally Disintegrating Meloxicam Tablet

The FDA has approved Qmiiz ODT (TerSera), an orally disintegrating tablet formulation of the prescription NSAID meloxicam. Qmiiz ODT , like conventional oral meloxicam tablets ( Mobic , and generics), is…

Med Lett Drugs Ther. 2019 Sep 23; 61(1581):151-2
The FDA has approved Qmiiz ODT (TerSera), an orally disintegrating tablet formulation of the prescription NSAID meloxicam. Qmiiz ODT , like conventional oral meloxicam tablets ( Mobic , and generics), is indicated for relief of the symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) in adults and of juvenile RA in children who weigh ≥60 kg. Vivlodex , a low-dose capsule formulation of meloxicam, is FDA-approved only for management of OA pain.
Issue 1554 · August 27, 2018
Two New Intra-Articular Injections for Knee Osteoarthritis

The FDA has approved a single-injection hyaluronic acid gel ( Durolane – Bioventus) and an extended-release (ER) formulation of the synthetic corticosteroid triamcinolone acetonide ( Zilretta – Flexion)…

Med Lett Drugs Ther. 2018 Aug 27; 60(1554):142-4
The FDA has approved a single-injection hyaluronic acid gel ( Durolane – Bioventus) and an extended-release (ER) formulation of the synthetic corticosteroid triamcinolone acetonide ( Zilretta – Flexion) for intra-articular (IA) treatment of osteoarthritic knee pain.
Issue 1540 · February 12, 2018
Comparison Table: Some Nonopioid Analgesics for Pain (online only)

View the Comparison Table: Some Nonopioid Analgesics for Pain

Med Lett Drugs Ther. 2018 Feb 12; 60(1540):e32-5
View the Comparison Table: Some Nonopioid Analgesics for Pain
Issue 1510 · December 19, 2016
Celecoxib Safety Revisited

The results of a clinical trial (PRECISION) comparing the cardiovascular safety of the COX-2 selective NSAID celecoxib ( Celebrex , and generics) with that of ibuprofen and naproxen, which are nonselective,…

Med Lett Drugs Ther. 2016 Dec 19; 58(1510):159
The results of a clinical trial (PRECISION) comparing the cardiovascular safety of the COX-2 selective NSAID celecoxib ( Celebrex , and generics) with that of ibuprofen and naproxen, which are nonselective, have been described in the lay press in terms that may overestimate the safety of celecoxib.
Issue 1490 · March 14, 2016
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain

The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam ( Mobic , and generics), for management of osteoarthritis pain. According to the manufacturer,…

Med Lett Drugs Ther. 2016 Mar 14; 58(1490):35-6
The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam ( Mobic , and generics), for management of osteoarthritis pain. According to the manufacturer, the new formulation aligns with stronger FDA warnings about the cardiovascular risks of NSAIDs and the recommendation to use the lowest possible doses of these drugs.
Issue 1450 · September 1, 2014
Drugs for Osteoarthritis

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management,…

Med Lett Drugs Ther. 2014 Sep 1; 56(1450):80-4
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management, exercise, physical therapy, assistive devices, and total joint arthroplasty. New guidelines for the management of osteoarthritis have recently been published.
Issue 1437 · March 3, 2014
Low-Dose Diclofenac (Zorvolex) for Pain

The FDA has approved Zorvolex (Iroko) , a low-dose oral formulation of the relatively COX-2 selective NSAID diclofenac, for treatment of mild-to-moderate acute pain in adults.

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):19-20
The FDA has approved Zorvolex (Iroko) , a low-dose oral formulation of the relatively COX-2 selective NSAID diclofenac, for treatment of mild-to-moderate acute pain in adults.
Issue 1376 · October 31, 2011
A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)

The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of…

Med Lett Drugs Ther. 2011 Oct 31; 53(1376):85-6
The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo , a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.
Issue 1363 · May 2, 2011
Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain

Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia, duloxetine ( Cymbalta – Lilly) has now also been approved for…

Med Lett Drugs Ther. 2011 May 2; 53(1363):33-4
Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia, duloxetine ( Cymbalta – Lilly) has now also been approved for treatment of chronic musculoskeletal pain.
Issue 1362 · April 18, 2011 Free
In Brief: Does Acetaminophen Increase Blood Pressure?

A recent article in Circulation reported that acetaminophen ( Tylenol , and others; paracetamol outside the US) increased blood pressure in patients with coronary artery disease. This conclusion was based on a…

Med Lett Drugs Ther. 2011 Apr 18; 53(1362):29
A recent article in Circulation reported that acetaminophen ( Tylenol , and others; paracetamol outside the US) increased blood pressure in patients with coronary artery disease. This conclusion was based on a randomized, placebo-controlled crossover trial in 33 patients; acetaminophen 1 g three times daily for 2 weeks was associated with statistically significant increases in blood pressure of 2.9 mmHg systolic and 2.2 mmHg diastolic. 1 NSAIDs can increase blood pressure; the mechanism is thought to be inhibition of cyclooxygenase leading to decreased renal prostaglandin activity. Acetaminophen also inhibits cyclooxygenase (primarily COX-2) and decreases prostaglandin activity. 2 The small increases in blood pressure reported with acetaminophen would probably be inconsequential in low-risk patients, but might be a concern for those with cardiovascular disease. Like most drugs, acetaminophen should be used in the lowest effective doses for the shortest possible time. Mild to moderate pain due to osteoarthritis or headache generally responds to a dose of 650 mg. 3 1. I Sudano et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010; 122:1789. 2. B Hinz et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008; 22:383. 3. Drugs for pain. Treat Guidel Med Lett 2010; 8:25. Download U.S. English
Issue 1347 · September 20, 2010
Naproxen/Esomeprazole (Vimovo)

The FDA has approved the marketing of Vimovo (AstraZeneca), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) naproxen and the proton pump inhibitor (PPI) esomeprazole, for…

Med Lett Drugs Ther. 2010 Sep 20; 52(1347):74-5
The FDA has approved the marketing of Vimovo (AstraZeneca), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) naproxen and the proton pump inhibitor (PPI) esomeprazole, for symptomatic relief of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk for NSAID-associated ulcers.
Issue 1316 · July 13, 2009
Acetaminophen Safety - Deja Vu

Concerns have surfaced again at the FDA and in the media about the safety of acetaminophen and the multiplicity of products on the market in the US that contain various amounts of it.

Med Lett Drugs Ther. 2009 Jul 13; 51(1316):53-4
Concerns have surfaced again at the FDA and in the media about the safety of acetaminophen and the multiplicity of products on the market in the US that contain various amounts of it.
Issue 1284 · April 21, 2008
Diclofenac Gel For Osteoarthritis

The nonsteroidal anti-inflammatory drug (NSAID) diclofenac, has been approved by the FDA in a 1% topical gel formulation ( Voltaren Gel - Endo) for treatment of osteoarthritis (OA). A 3% topical diclofenac gel…

Med Lett Drugs Ther. 2008 Apr 21; 50(1284):31-2
The nonsteroidal anti-inflammatory drug (NSAID) diclofenac, has been approved by the FDA in a 1% topical gel formulation ( Voltaren Gel - Endo) for treatment of osteoarthritis (OA). A 3% topical diclofenac gel ( Solaraze ) is currently approved for treatment of actinic keratoses, but not for topical use on joints. No other topical NSAIDs are approved by the FDA for OA. A diclofenac patch ( Flector ) was recently approved by the FDA for treatment of pain due to minor strains, sprains and contusions.
Issue 1234 · May 8, 2006
Acupuncture

Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that…

Med Lett Drugs Ther. 2006 May 8; 48(1234):38-9
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Issue 1231 · March 27, 2006
Intra-Articular Injections for Osteoarthritis of the Knee

Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives.…

Med Lett Drugs Ther. 2006 Mar 27; 48(1231):25-7
Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives. One of these is periodic intra-articular injection of a corticosteroid or hyaluronic acid preparation.
Issue 1200 · January 17, 2005
NSAID Alternatives

Patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) may be asking their health care providers if they should continue, and some may be asking for alternatives. For most patients taking nonspecific…

Med Lett Drugs Ther. 2005 Jan 17; 47(1200):8
Patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) may be asking their health care providers if they should continue, and some may be asking for alternatives. For most patients taking nonspecific NSAIDs, it would be reasonable to continue. For those who are taking the COX-2 selective celecoxib ( Celebrex ) because they cannot tolerate the gastrointestinal (GI) effects of nonspecific NSAIDs, it seems reasonable to continue at doses no higher than 100 mg b.i.d. or 200 mg once daily; at these dosages cardiovascular risk has been no higher than with placebo. All NSAIDs, including COX-2 inhibitors, can decrease renal blood flow and cause fluid retention, hypertension and renal failure, especially in the elderly and in patients who take diuretics. The unpublished study that led to an FDA alert on an increased cardiovascular risk with naproxen ( Naprosyn , and others) was conducted in patients older than 70. See NSAID addendum
Issue 1129 · April 29, 2002
Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor

Valdecoxib ( Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx) , was recently approved by the FDA for treatment of osteoarthritis,…

Med Lett Drugs Ther. 2002 Apr 29; 44(1129):39-41
Valdecoxib ( Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx) , was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.
Issue 1079 · May 29, 2000
Meloxicam (Mobic) for Osteoarthritis

Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with some cyclooxygenase-2 (COX-2) selectivity in vitro, has been approved by the FDA for treatment of osteoarthritis.

Med Lett Drugs Ther. 2000 May 29; 42(1079):47-8
Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with some cyclooxygenase-2 (COX-2) selectivity in vitro, has been approved by the FDA for treatment of osteoarthritis.
Issue 1056 · July 2, 1999
Rofecoxib for Osteoarthritis and Pain

Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.
Issue 868 · April 17, 1992
Nabumetone - A New Nsaid

Nabumetone ( Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis.…

Med Lett Drugs Ther. 1992 Apr 17; 34(868):38-40
Nabumetone ( Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987. The manufacturer claims that nabumetone is as effective as other NSAIDs and causes a relatively low incidence of peptic ulcers.
Issue 851 · August 23, 1991
Etodolac

Etodolac ( Lodine - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID) available in Europe for several years, was recently approved by the U.S. Food and Drug Administration for use in osteoarthritis…

Med Lett Drugs Ther. 1991 Aug 23; 33(851):79-80
Etodolac ( Lodine - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID) available in Europe for several years, was recently approved by the U.S. Food and Drug Administration for use in osteoarthritis and as a general-purpose analgesic. It has not been approved for treatment of rheumatoid arthritis.
Issue 789 · April 7, 1989
Flurbiprofen

Flurbiprofen ( Ansaid - Upjohn), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1977, was recently approved by the US Food and Drug Administration for treatment of rheumatoid…

Med Lett Drugs Ther. 1989 Apr 7; 31(789):31-2
Flurbiprofen ( Ansaid - Upjohn), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1977, was recently approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. Flurbiprofen is a fluorinated phenylalkanoic acid derivative structurally related to ibuprofen ( Motrin ;and others).
Issue 780 · December 2, 1988
Diclofenac

Diclofenac sodium ( Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis,…

Med Lett Drugs Ther. 1988 Dec 2; 30(780):109-11
Diclofenac sodium ( Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is being promoted as 'The number one prescribed antiarthritic in the world.'